# Pharmaceutical Business
# Clinical Development as of October 31, 2024

＜In-house development＞

| Code (Generic Name) | Potential Indication/Dosage form | Mechanism | | Phase (Region) | Origin | Note |
|---|---|---|---|---|---|---|
| JTE-052 (delgocitinib) | Autoimmune/allergic diseases /Oral, Topical | JAK inhibitor | Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal. | Phase1 (Japan) | In-house | |
| JTE-051 | Autoimmune/allergic diseases /Oral | Interleukin-2 inducible T cell kinase inhibitor | Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response. | Phase2(Japan)<br>Phase2 (Overseas) | In-house | |
| JTT-662 | Type 2 diabetes mellitus /Oral | SGLT1 inhibitor | Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1. | Phase1 (Overseas) | In-house | |
| JTT-861 | Chronic heart failure /Oral | PDHK inhibitor | Improves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. | Phase2 (Overseas) | In-house | |
| JTE-061 (tapinarof) | Atopic dermatitis (pediatric) /Topical | AhR modulator | Suppresses skin inflammation via activation of the aryl hydrocarbon receptor (AhR) | Phase3 (Japan) | In-license | ・In-license from Dermavant Sciences GmbH<br>・Co-development with Torii |
| JTC-064 | Neurodegenerative disease /Oral | PDHK inhibitor | Improves metabolic abnormalities by activation of pyruvate dehydrogenase (PDH) | Phase1 (Overseas) | In-house | |
| JTV-161 | Pulmonary arterial hypertension /Oral | Pim-1 inhibitor | Suppresses pulmonary vascular cell proliferation by inhibiting Pim-1 | Phase1 (Overseas) | In-house | |
| JTE-162 | Autoinflammatory/ Autoimmune diseases /Oral | NLRP3 inhibitor | Suppresses immune response by inhibition of NLRP3 inflammasome | Phase1 (Overseas) | In-house | |
| JTV-261 | Thrombosis /Oral | PLD1/2 inhibitor | Suppresses shear-dependent platelet aggregation by inhibiting PLD1/2 | Phase1 (Japan) | In-house | |
| JTC-262 | Neurodegenerative disease /Oral | NLRP3 inhibitor | Suppresses immune response by inhibition of NLRP3 inflammasome | Phase1 (Overseas) | In-house | |
| JTV-263 | Peripheral artery disease /Oral | H-PGDS inhibitor | Improve blood flow in ischemic lower extremities by inhibiting H-PGDS | Phase1 (Overseas) | In-house | |

Clinical trial phase presented above is based on the first dose.
We are also conducting additional studies to examine the potential for use in additional dosage forms.

＜Licensed compounds＞

| Compound (JT's code) | Licensee | Mechanism | | Note |
|---|---|---|---|---|
| trametinib | Novartis | MEK inhibitor | Inhibits cellular growth by specifically inhibiting the activity of MAPK/ERK pathway. | |
| delgocitinib | LEO Pharma<br>ROHTO Pharmaceutical | JAK inhibitor | Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal. | |
| enarodustat | JW Pharmaceutical<br>Salubris | HIF-PH inhibitor | Increases red blood cells by stimulating production of erythropoietin, an erythropoiesis-stimulating hormone, via inhibition of HIF-PH. | |

Updates since the previous announcement on August 2, 2024

・JTV-261 has entered the clinical trial stage (Phase1) in Japan.

・JTC-262 has entered the clinical trial stage (Phase1) in overseas.

・JTV-263 has entered the clinical trial stage (Phase1) in overseas.

・delgocitinib : JT's license partner LEO Pharma issued a statement that the U.S. Food and Drug Administration has accepted its New Drug Application for delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema. (September 23, 2024)

・delgocitinib : JT's license partner LEO Pharma issued a statement that the European Commission has approved delgocitinib cream (Anzupgo®) for the treatment of adult patients with moderate to severe chronic hand eczema. (September 23, 2024)